Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease Two separate Phase I studies conducted in Australia and in China indicate… CISION PRNewswireJanuary 7, 2025
Press ReleaseAiDot Offers Exclusive Foretaste of Cutting-Edge Smart Home Innovations at CES 2025 LAS VEGAS, Jan. 7, 2025 /PRNewswire/ — AiDot, a leading innovator in… CISION PRNewswireJanuary 7, 2025
GSCF Acquires IBM Deutschland Kreditbank GmbH Extends Connected Capital Ecosystem of Corporates and Bank Partners for Coverage Across… CISION PRNewswireJanuary 7, 2025
Press ReleaseTechAxonify Receives Gold and Silver in Brandon Hall Group's 2024 Excellence in Technology Awards Recognized with Gold Award for "Best Advance in Learning Management Measurement/Business Impact… CISION PRNewswireJanuary 7, 2025
Webull Canada Celebrates First Anniversary TORONTO, Jan. 7, 2025 /PRNewswire/ — Webull Canada, a subsidiary of Webull… CISION PRNewswireJanuary 7, 2025
Press ReleaseAvenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing… CISION PRNewswireJanuary 7, 2025
Press ReleaseHesai Unveils Mini Hyper-Hemispherical 3D Lidar Series for Robotics at CES Hesai (Nasdaq: HSAI) introduces new JT series mini 3D lidar, with compact… CISION PRNewswireJanuary 7, 2025
Press ReleaseTwo New Products at CES: Hesai Showcases 1440-Channel Automotive Lidar and Next Gen Solid-State Lidar Hesai (Nasdaq: HSAI) introduces new AT1440 with the world’s highest number of… CISION PRNewswireJanuary 7, 2025
